Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
2010
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
2002
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
2014 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
2006
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
2008
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
2011
Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer
2006
Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy
2001
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
2009
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Molybdenum Disulfide‐Based Tubular Microengines: Toward Biomedical Applications
2016
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
2013 Standout
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer
2003
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
2001
Targeting hypoxia in cancer therapy
2011 Standout
Breast cancer
2016 Standout
Sentinel lymph node biopsy in breast cancer
2002
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Head and neck cancer
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study
2002 Standout
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
2002
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial)
2017
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping
2003 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
2010
DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design
2006
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
2004
Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review
2009
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients
2006
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer
2002
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
2010
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
2002
Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients
2006
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
2013 Standout
Is there a Reliable Method to Assess the Complete Pathologic Response on the Tumor after Neo-adjuvant Chemotherapy in Inflammatory Breast Cancer toward Recommendations for the Pathologic Process? Experience in 56 Patients Treated in a Single Institution
2010
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients
2009
American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome
2005
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
2015
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
2005
Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome
2003
Preliminary Outcome Analysis in Patients With Breast Cancer and a Positive Sentinel Lymph Node Who Declined Axillary Dissection
2003
Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy
2005
Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients
2014
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
2003
Sentinel Lymph Node Mapping Following Neoadjuvant Chemotherapy for Breast Cancer
2002
Breast cancer metastasis: markers and models
2005 Standout
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques
2011
Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
2001
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy
2003
Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes
2002
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
2007
The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial
2004
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
2005
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2003
Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?
2001
Neoadjuvant chemotherapy for breast carcinoma
2003
Correlation Between Clinical Nodal Status and Sentinel Lymph Node Biopsy False Negative Rate After Neoadjuvant Chemotherapy
2012
Positron Emission Tomography Using [18F]-Fluorodeoxy-d -Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
2000
Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications
2005
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
2003
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
2000
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
2005 Standout
Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
2005
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
2015
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
2005
Dynamic contrast‐enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
2014
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiothérapie Neoadjuvante, a French Prospective Multicentric Study
2008
Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
2005
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
2005
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
2005
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
2016
Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases
2007
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
2006
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2006
Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
2004
Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study
2001
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Primary Systemic Therapy of Breast Cancer
2006
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
2006
Works of Fred C. Ames being referenced
Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients
1999
Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy
1999
Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer
2000
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer
1998
The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy
2000
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
1999